Press release
Strategic Forecast for the Hypertrophic Cardiomyopathy (HCM) Therapeutics Industry: Market Outlook 2025-2034
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In the past few years, there has been a slight increase in the size of the Hypertrophic Cardiomyopathy (HCM) therapeutics market. It's estimated to expand from $1.34 billion in 2024 to $1.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 1.8%. The uptick observed during this historic period is due to advancements in diagnostics, heightened disease awareness, advancements in drug development and approvals, escalating healare expenses, together with government initiatives and funding.
How Will the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Evolve and Grow by 2029?
Expectations are high for consistent growth in the hypertrophic cardiomyopathy (HCM) therapeutics market size over the coming years. The market is projected to mature to $1.57 billion by 2029 with a compound annual growth rate (CAGR) of 3.4%. This growth for the forecast period is mainly due to factors such as genetic research, personalized medicinal approaches, emerging therapeutic modalities, joint research endeavors, and local health initiatives. The major trends to watch for within this forecast period include advancements in personalized medicine and genetic testing, broadening drug pipeline, industry collaborations and partnerships, along with a stronger focus on patient-centric methodologies.
View the full report here:
https://www.thebusinessresearchcompany.com/report/hypertrophic-cardiomyopathy-hcm-therapeutics-global-market-report
What Drivers Are Propelling the Growth of Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Forward?
The surge in the prevalence of cardiovascular diseases (CVD) is anticipated to drive the expansion of the hypertrophic cardiomyopathy (HCM) therapeutics market. CVD, a health issue that impacts the heart and blood vessels, encompasses heart abnormalities like atrial fibrillation, ventricular fibrillation, and atrioventricular block which require extended monitoring. The fundamental aim of therapeutic treatment for hypertrophic cardiomyopathy is to alleviate symptoms and prevent sudden cardiac death in patients at high risk. For example, as per the report of the Center for Disease Control and Prevention (CDCP), a national public health institute in the United States in October 2022, every 36 seconds a person dies from CVD in the United States, and CVD was responsible for almost 836,546 deaths exclusively in the US in 2021. Consequently, the escalating prevalence of cardiovascular diseases (CVD) fuels the hypertrophic cardiomyopathy (HCM) therapeutics market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9914&type=smp
Which Emerging Trends Are Transforming the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market in 2025?
The hypertrophic cardiomyopathy (HCM) therapeutics market is witnessing a surge in adoption of product innovations as a primary trend. Top companies in the cardiomyopathy therapeutics industry are concentrating their efforts on designing novel and innovative products to consolidate their market standing. For instance, Bristol Myers Squibb, a biopharmaceutical corporation based in the US, rolled out Camzyos (mavacamten), an oral cardiac myosin inhibitor drug in April 2022. This small molecule is designed for treating hypertrophic cardiomyopathy (HCM) and diseases resulting from heart diastolic dysfunction. The US Food and Drug Administration (FDA) gave approval for its use in treating adults suffering from symptomatic class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to restore functional capacity and symptoms. Camzyos is unique as it's the solitary FDA-approved allosteric and reversible inhibitor of cardiac myosin directly aimed at correcting the inherent pathophysiology of obstructive HCM. Camzyos effectively regulates the count of myosin heads that are allowed to enter the power-generating 'on actin' states.
What Are the Key Segments in the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market?
The hypertrophic cardiomyopathy (HCM) therapeutics market covered in this report is segmented -
1) By Drug Type: Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types
2) By Device Type: Defibrillators, Pacemakers, Other Device Types
3) By End User: Hospitals, Clinics
Subsegments:
1) By Antiarrhythmic Agents: Class I Agents, Class II Agents, Class III Agents, Class IV Agents
2) By Anticoagulants: Vitamin K Antagonists, Direct Oral Anticoagulants (DOACs), Low Molecular Weight Heparins (LMWH)
3) By Beta Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
5) By Other Drug Types: Myosin Inhibitors, Antimetabolites, Other Novel Agents
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9914&type=smp
Who Are the Key Players Shaping the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market's Competitive Landscape?
Major companies operating in the hypertrophic cardiomyopathy (HCM) therapeutics market include Merck & Co. Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Correvio Pharma Corp., Advanz Pharma Corp., Lupin Limited, Boston Scientific Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, Medtronic plc, Cardiome Pharma Corp., Cytokinetics Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., HUYA Bioscience International LLC, Ionis Pharmaceuticals Inc., Kowa Company Ltd., Luitpold Pharmaceuticals Inc., Menarini Group, Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Servier Laboratories
What Geographic Markets Are Powering Growth in the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market?
North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in the hypertrophic cardiomyopathy (HCM) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9914
This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Strategic Forecast for the Hypertrophic Cardiomyopathy (HCM) Therapeutics Industry: Market Outlook 2025-2034 here
News-ID: 4089216 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for HCM
HCM Suite Application Market: USD 30.2 billion Valuation by Key Players:SAP Succ …
New Jersey, US State: "The global HCM Suite Application market in the Information Technology and Telecom category is projected to reach USD 30.2 billion by 2031, growing at a CAGR of 8.5% from 2025 to 2031. With rising industrial adoption and continuous inOctation in Information Technology and Telecom applications, the market is estimated to hit USD 15.5 billion in 2024, highlighting strong growth potential throughout the forecast period."
HCM Suite Application…
Evolving Market Trends In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Ind …
The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Its Estimated Growth Rate?
In the past few years, the hypertrophic cardiomyopathy (HCM) therapeutics market has seen a minor increase in its…
Evolving Market Trends In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Ind …
The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Its Estimated Growth Rate?
In the past few years, the hypertrophic cardiomyopathy (HCM) therapeutics market has seen a minor increase in its…
Human Capital Management (HCM) Market to Witness Huge Growth by 2019-2025 | Ceri …
A new business intelligence report released by HTF MI with title “Global Human Capital Management (HCM) Market 2019-2025” that targets and provides comprehensive market analysis with future prospects to 2025. The rapid decision-making power of market research and consumer insight is never more valuable than in times of crisis. The analysts of the study have utilized extensive research methodologies and data sources (i.e Secondary & Primary Sources) in order to…
Human Capital Management (HCM) Market to see Booming Worldwide | Ceridian HCM, O …
A qualitative research study accomplished by HTF MI titled “Global Human Capital Management (HCM) Market covers detailed Product / Industry Scope, current and future market size scenario and elaborates outlook and status to 2025” provides primary data, studies and vendor briefings. The market Study is segmented by key regions along with country level break-up which is accelerating the marketization and by products type, application/end-users. The research study provides estimates for…
Human Capital Management (HCM) & Payroll - Great Market, Know Players Growth Rat …
The Exploration study offers deep assessment of the Global Human Capital Management (HCM) & Payroll Market and helps market participants to gain a solid base in the industry. The Research report presents a complete assessment of the market and contains Future trend, Current Growth Factors, attentive opinions, historical data, facts and statistically supported and industry certified market data. It delivers regional exploration of the Global Human Capital Management (HCM) &…
